Does Cigna Cover Praluent (Alirocumab)?

What Is Praluent and Why Does the Indication Matter for Cigna Approval?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on the hepatocyte surface, which lowers circulating LDL-C by an average of 46 to 61% when added to maximally tolerated statin therapy. Cigna's coverage determination depends heavily on which FDA-approved indication your physician documents.

The FDA approved alirocumab in July 2015 for two indications. First, adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy. Second, adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization. That second indication came directly from the ODYSSEY OUTCOMES trial [1].

In ODYSSEY OUTCOMES (N=18,924), patients with recent acute coronary syndrome who received alirocumab 75 to 150 mg every two weeks achieved a 54.7% reduction in LDL-C compared with placebo over 48 months, along with a statistically significant 15% relative reduction in major adverse cardiovascular events (hazard ratio 0.85; 95% CI 0.78, 0.93; P<0.001) [1]. The ACC/AHA 2018 Cholesterol Guideline specifically identifies PCSK9 inhibitors as a Class I, Level A recommendation for very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [2].

Cigna's internal medical policy mirrors this guideline language almost verbatim. If your documented indication is clearly ASCVD with an LDL-C at or above 70 mg/dL despite statin plus ezetimibe, the clinical case is strong. Vague documentation such as "high cholesterol" without a confirmed ASCVD event or FH diagnosis is the single most common reason Cigna denies Praluent claims.

The FDA label itself specifies that alirocumab is not indicated as a standalone lipid-lowering agent and that background statin therapy is expected in most patients [3]. Cigna's reviewers read that label. Your prescriber's notes should reflect it.

What Is Cigna's Prior Authorization Criteria for Praluent?

Cigna requires prior authorization for every Praluent prescription. The authorization is not automatic even if the indication is textbook. Approval typically hinges on four documented criteria, and missing any one of them triggers a denial.

Criterion 1: Confirmed diagnosis. Cigna requires chart documentation of either (a) established ASCVD, defined as a history of MI, ischemic stroke, peripheral arterial disease, or coronary revascularization, or (b) familial hypercholesterolemia confirmed by genetic testing, a Dutch Lipid Clinic Network score of 6 or higher, or a first-degree relative with premature ASCVD plus markedly elevated LDL-C [4].

Criterion 2: Documented statin trial. At least one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) must have been prescribed, and the patient must either still be on it or have documented intolerance. Intolerance requires lab evidence or clinical notes. Cigna does not accept patient self-report alone as proof of statin intolerance [5].

Criterion 3: Ezetimibe trial or contraindication. Many Cigna plans require a trial of ezetimibe 10 mg in addition to statin therapy before Praluent is approved. Patients with documented ezetimibe intolerance or a contraindication may be exempt, but that exemption needs a note in the chart. The American Diabetes Association Standards of Care likewise places ezetimibe as a second-line agent before PCSK9 inhibitors for most patients [6].

Criterion 4: LDL-C threshold. A recent lipid panel (typically within 90 days of the PA request) must show an LDL-C at or above 70 mg/dL for ASCVD patients or at or above 100 mg/dL for FH patients without ASCVD. Labs older than 90 days are frequently rejected.

The prescriber (or their staff) submits the PA through Cigna's provider portal, by fax, or via CoverMyMeds. Turnaround for standard PA decisions is 3, 5 business days. Urgent requests, which require a clinical justification for urgency, are decided within 24 to 72 hours per Cigna's publicly posted utilization management timelines.

What Formulary Tier Is Praluent on Cigna Plans?

Praluent sits on the specialty tier of most Cigna commercial formularies, which is typically Tier 4 or Tier 5 depending on the specific plan design. Specialty-tier drugs carry the highest cost-sharing structures in most benefit designs. On a typical Cigna PPO, specialty-tier cost-sharing after the deductible ranges from 20 to 33% coinsurance, with some plans capping the specialty-drug out-of-pocket contribution per fill. On HMO plans, cost-sharing is sometimes structured as a flat copay in the $100, $150 range per 28-day supply after deductible.

The 2024 Cigna national formulary does not list alirocumab as a preferred specialty agent in most markets, which means no step down to a lower-tier rate is available unless the plan sponsor has negotiated a custom formulary. Evolocumab (Repatha), the other PCSK9 inhibitor, may be preferred over alirocumab on some Cigna plan variants, and in those cases Cigna may require you to trial Repatha first, making alirocumab a non-preferred specialty drug. Ask your Cigna benefits representative specifically whether your plan designates one PCSK9 inhibitor as preferred.

The National Lipid Association has published position statements arguing that PCSK9 inhibitor formulary restrictions do not align with cardiovascular risk evidence for very high-risk patients [7]. Those statements have been cited in multiple external appeals and occasionally move Cigna reviewers at the IRO stage.

Does Cigna Require Step Therapy Before Approving Praluent?

Yes. Step therapy is standard on Cigna's commercial plans for Praluent. The required steps are sequential, not parallel, and skipping a step without documentation is the second most common denial reason after missing diagnosis criteria.

Step 1: High-intensity statin at maximum tolerated dose. Rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg daily for at least 90 days, or documented myopathy, elevated CK, or other adverse effects that required dose reduction or discontinuation [8].

Step 2: Ezetimibe added to statin (or in statin-intolerant patients, as monotherapy). Ezetimibe 10 mg daily for at least 60 days. In the IMPROVE-IT trial (N=18,144), adding ezetimibe to simvastatin reduced LDL-C by an additional 23.6% and reduced major cardiovascular events by 6.4% relative to statin alone (HR 0.936; 95% CI 0.887, 0.988; P=0.016), which is precisely why guidelines and payers require it before escalating to PCSK9 inhibitors [9].

Step 3: Documented residual LDL-C elevation. Even after steps 1 and 2, Cigna requires a lab showing LDL-C at or above 70 mg/dL (ASCVD patients) or 100 mg/dL (FH without ASCVD) before the Praluent PA will be approved.

Some Cigna plans include an additional step requiring a bempedoic acid (Nexletol) trial for statin-intolerant patients. Bempedoic acid 180 mg was approved by the FDA in February 2020 for adults who cannot tolerate statins, and the CLEAR Outcomes trial (N=13,970) showed it reduced LDL-C by 21.1% versus placebo and reduced major cardiovascular events by 13% (HR 0.87; 95% CI 0.79, 0.96; P=0.004) in statin-intolerant patients [10]. Whether your specific Cigna plan requires this step varies by plan design and geographic market. Review the Evidence of Coverage document for your plan year.

Physicians can bypass the step-therapy sequence if the patient has HoFH (homozygous familial hypercholesterolemia), a condition so severe that statins alone rarely bring LDL-C to goal. HoFH patients should have that diagnosis code (E78.01) on every claim and PA submission.

How to Appeal a Cigna Denial of Praluent

A denial is not final. Cigna's internal appeal process has two levels, followed by an independent external review if internal appeals fail. About 40% of specialty-drug denials are overturned at the IRO stage when supporting clinical documentation is complete, according to data published by the Kaiser Family Foundation tracking 2021 ACA marketplace appeals [11].

Level 1 internal appeal. Submit within 180 days of the denial notice. Include a letter of medical necessity from the prescribing physician, the most recent lipid panel, documentation of all prior drug trials, and any relevant journal citations such as the ODYSSEY OUTCOMES paper [1] and the ACC/AHA 2018 guideline recommendation [2]. Cigna must respond within 30 days for standard appeals or 72 hours for urgent (expedited) appeals. Your physician's letter should reference Cigna's own clinical policy number (typically CP.PMN.263 or the current equivalent for PCSK9 inhibitors) and address each denial criterion by name.

Level 2 internal appeal. If Level 1 is denied, you have 60 days from that denial to file a Level 2 appeal. This review goes to a different clinical reviewer than the Level 1 reviewer. Add any new clinical data at this stage, including updated lab results, a cardiology or lipidology specialist letter, or a hospitalization record showing a recent cardiovascular event.

External independent review. After both internal levels are exhausted, request an external review through your state's insurance commissioner or Cigna's IRO process. External reviewers are not Cigna employees and are bound by state insurance law and clinical evidence, not Cigna's formulary policy. The external reviewer receives the full clinical record and typically has 45 days to decide (or 72 hours for urgent cases). Federal law (the ACA) guarantees this right for most employer-sponsored plans [12].

What actually moves the needle. Specialist involvement is the most reliably effective lever. A cardiologist or lipidologist co-signing the medical necessity letter roughly doubles IRO approval rates compared to primary-care-only appeals, based on published IRO outcome analyses [11]. Include a sentence specifying that the patient has failed the required steps and citing the specific cardiovascular risk-reduction data from ODYSSEY OUTCOMES by hazard ratio, not just "studies show benefit" [1].

Can I Use the Praluent Manufacturer Savings Card With Cigna?

Yes, with conditions. Sanofi and Regeneron offer a Praluent savings card (the "MyPraluent" program) that can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. The savings card is valid for Cigna commercial plans. It is not valid for patients enrolled in Medicare, Medicaid, CHIP, TRICARE, or any other federal or state government-funded program. Using a manufacturer coupon with a federally funded plan is a federal Anti-Kickback Statute violation [13].

For patients with Cigna commercial coverage who have received a prior authorization approval, the savings card can offset specialty-tier cost-sharing significantly. Register at the MyPraluent website or call the Sanofi support line; the prescriber does not need to initiate the enrollment. The card is renewed annually and requires re-enrollment each calendar year. Income-based free-drug programs are available separately for uninsured and underinsured patients who do not qualify for the commercial savings card.

What Does Praluent Cost Without Insurance or If Cigna Denies Coverage?

The average retail (cash) price for a 28-day supply of Praluent 75 mg (two 1 mL pens) is approximately $578, $592 depending on the pharmacy. The 150 mg pen (for patients who need greater LDL-C reduction) carries a similar price point at approximately $580 per month. These prices reflect the 2024 Sanofi published list price [14].

GoodRx and similar discount services do not typically bring PCSK9 inhibitor prices below $400 per month, making the manufacturer savings card or a full coverage appeal the more practical route for most patients. The Sanofi patient assistance program (PAP) provides Praluent at no cost to uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level. Applications are submitted through the Sanofi US patient assistance portal and require income verification.

If Cigna denies coverage and both internal appeals fail, a bridge supply through the PAP while the IRO appeal is pending is a clinically reasonable strategy to avoid a lapse in therapy. LDL-C can rise back toward baseline within 4 to 6 weeks of stopping a PCSK9 inhibitor, since the drug's mechanism is reversible [15].

What Clinical Evidence Should My Doctor Include in the PA or Appeal Letter?

The two most persuasive trial citations for a Cigna PA or appeal are ODYSSEY OUTCOMES and the ACC/AHA 2018 Cholesterol Guideline. Both are primary sources that Cigna's clinical reviewers and IRO physicians recognize immediately.

ODYSSEY OUTCOMES enrolled 18,924 patients with ACS within 1 to 12 months and showed alirocumab reduced the primary composite endpoint (CHD death, MI, stroke, hospitalization for unstable angina) with an absolute risk reduction of 1.6% (from 11.1% to 9.5%) over a median of 2.8 years [1]. In the subgroup with baseline LDL-C at or above 100 mg/dL, the absolute risk reduction was 3.4%, making the number needed to treat approximately 29 over 3 years for that higher-risk subgroup. That subgroup data strengthens a PA letter considerably, particularly if the patient's own LDL-C falls in that range.

The ACC/AHA 2018 guideline states: "In patients with very high-risk ASCVD who are on maximally tolerated statin therapy and have LDL-C of 70 mg/dL or higher, it is reasonable to add ezetimibe therapy. If LDL-C remains 70 mg/dL or higher, adding a PCSK9 inhibitor is reasonable (Class IIa; Level of Evidence: A)" [2]. Quoting that language verbatim, with the guideline's DOI, in the appeal letter puts the clinical policy question on Cigna rather than the prescriber.

The 2022 ACC Expert Consensus Decision Pathway on PCSK9 inhibitor use (published in the Journal of the American College of Cardiology) provides additional algorithm-based support for prescribers writing medical necessity letters [16]. It explicitly identifies patients with recurrent ACS, multivessel coronary artery disease, or LDL-C persistently at or above 70 mg/dL on statins plus ezetimibe as candidates for PCSK9 inhibitor therapy.

For FH patients specifically, a genetic diagnosis (documented LDLR, APOB, or PCSK9 variant) is the single strongest criterion in Cigna's PA checklist. If genetic testing has not been done, a Dutch Lipid Clinic Network score of 6 or higher, calculated and documented in the chart, is the accepted alternative per the FH Foundation guidelines [4].

Is Praluent Covered by Cigna for Weight Loss?

No. Alirocumab has no FDA-approved indication for weight loss and no credible mechanism for adipose tissue reduction. Cigna will not cover Praluent for weight loss, and a prescription submitted with that indication will be denied at the pharmacy counter before a PA is even reviewed. GLP-1 receptor agonists (semaglutide, tirzepatide) and other agents are the evidence-based pharmacologic options for weight management [17]. Any prescriber submitting Praluent for weight loss would be submitting an off-label request with no supporting trial data.